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Objectives: To determine, in a multi-ethnic/racial, prospective SLE inception cohort, the 
frequency, attribution, clinical and autoantibody associations with lupus psychosis and 
the short and long-term outcome as assessed by physicians and patients. 
Methods: Patients were evaluated annually for 19 neuropsychiatric (NP) events including 
psychosis. SLE disease activity 2000, SLICC/ACR damage index and SF-36 scores were 
collected.  Time to event and linear regressions were used as appropriate. 
Results: Of 1,826 SLE patients, 88.8% were female, 48.8% Caucasian. The meanSD 
age was 35.1±13.3 years, disease duration 5.64.2 months and follow-up 7.44.5 years. 
There were 31 psychotic events in 28/1,826 (1.53%) patients and most [(26/28; 93%)] 
had a single event. In the majority of patients [20/25; (80%)] and events [28/31; (90%)] 
psychosis was attributed to SLE, usually within 3 years of SLE diagnosis. Positive 
associations [hazard ratio and 95% confidence interval [HR (95%CI)] with lupus 
psychosis were prior SLE NP events [3.59, (1.16, 11.14), male sex [3.0, (1.20, 7.50)], 
younger age at SLE diagnosis [(per 10 years younger), 1.45 (1.01, 2.07)] and African 
ancestry [4.59 (1.79, 11.76)]. By physician assessment most psychotic events resolved 
by the second annual visit following onset, in parallel with an improvement in patient 
reported SF-36 summary and subscale scores. 
Conclusion: Psychosis is an infrequent manifestation of NPSLE. Generally, it occurs 
early after SLE onset and has a significant negative impact on health status. As 
determined by patient and physician report, the short and long term outlook is good for 
most patients, though careful follow-up is required. 
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Neuropsychiatric (NP) events are one of the features of systemic lupus erythematosus 
(SLE) but their frequency and attribution to SLE or other causes is variable. Overall, 
approximately one third are caused directly by SLE (1), but for individual manifestations 
this varies between 0% and 100% (2, 3). The outcome for individual NPSLE 
manifestations, especially rare NP events, is derived from observational cohorts of well 
characterized patients followed over prolonged periods.  
 
One of the rarer NP events is lupus psychosis which is part of both the ACR (4) and 
SLICC (5) classification criteria for SLE. Characterized by delusions and hallucinations, it 
is a dramatic presentation of NPSLE (6, 7). It is one of the few manifestations of nervous 
system disease in SLE associated, albeit inconsistently, with a lupus specific 
autoantibody against ribosomal P (8-10). The infrequent occurrence of psychosis has 
limited the number of clinical studies and most consist of case series obtained by review 
of medical records.   
 
In the present study of lupus psychosis, we determined its frequency, attribution, clinical 
and autoantibody associations and the outcome assessed by physicians and patients in 
a large, multi-ethnic/racial, prospective, inception cohort of SLE patients. 
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Patients and Methods 
Research study network: The study was conducted by the Systemic Lupus International 
Collaborating Clinics (SLICC) (11), a network of 53 investigators in 43 academic medical 
centers in 16 countries. The current study involved 31 centers in 10 countries. Data were 
collected per protocol at enrollment and annually, submitted to the coordinating center in 
Halifax, Nova Scotia, Canada and entered into an Access database. Appropriate 
procedures ensured data quality, management and security. The Nova Scotia Health 
Authority central zone Research Ethics Board, Halifax, and each of the participating 
centers’ institutional research ethics review boards approved the study. 
 
Patients: Patients fulfilled the ACR classification criteria for SLE (4) which served as the 
date of diagnosis, and provided written informed consent. Enrollment was permitted up 
to 15 months following the diagnosis. Demographic variables, education and medication 
history were collected. Lupus-related variables included the SLE Disease Activity Index 
2000 (SLEDAI-2K) (12) and SLICC/ACR damage index (SDI) (13). Laboratory testing 
required to determine SLEDAI-2K and SDI scores was done at each center.   
 
Neuropsychiatric (NP) events: An enrollment window extended from 6 months prior to 
the diagnosis of SLE up to the actual enrollment date. NP events were characterized 
within this window using the ACR case definitions for 19 NP syndromes (14). The clinical 
diagnosis was supported by investigations, if warranted, as per the guidelines. Patients 
were reviewed annually with a 6-month window around the assessment date. New NP 
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events and the status of previous NP events since the last study visit were determined at 
each assessment.   
 
The ACR case definition for psychosis (14) is: (i) delusions or hallucinations without 
insight; (ii) causing clinical distress or impairment in social, occupational or other relevant 
areas of functioning; (iii) disturbance should not occur exclusively during delirium; (iv) not 
better accounted for by another mental disorder. Recurring episodes of psychosis and 
other NP events within the enrollment window or within a follow-up assessment period 
were recorded once for that period of observation. The date of the first episode was taken 
as the onset of the event. Once a NP event had resolved, a subsequent event of the same 
type was recorded as a new event. 
 
Attribution of NP events: As with other publications on the SLICC NPSLE inception 
cohort, similar decision rules were used to determine the attribution of NP events (15, 16). 
Factors considered included: (i) temporal onset of NP event(s) in relation to the diagnosis 
of SLE; (ii) concurrent non-SLE factor(s), such as potential causes (“exclusions”) or 
contributing factors (“associations”) for each NP syndrome in the glossary for the ACR 
case definitions of NP events (14). For psychosis the pre-specified potential alternative 
causes (“exclusions”) were (a) primary psychotic disorder unrelated to SLE (e.g. 
schizophrenia);  (b) substance or drug induced psychotic disorder; (c) psychologically 
mediated reaction to SLE (brief reactive psychosis with major stressor), and the pre-
specified potential contributing factors (“associations”) were (a) marked psychosocial 
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stress and (b) corticosteroids; (iii) finally “common” NP events in normal population 
controls as described by Ainiala et al (17) were identified and included isolated 
headaches, anxiety, mild depression (mood disorders failing to meet criteria for “major 
depressive-like episodes”), mild cognitive impairment (deficits in less than 3 of the 8 
specified cognitive domains) and polyneuropathy without electrophysiological 
confirmation. Using these three factors, two attribution decision rules of different 
stringency (models A and B) were used (15, 16).  
Attribution model A (most stringent):  NP events which had their onset within the 
enrollment window and had no “exclusions” or “associations” and were not one of the NP 
events identified by Ainiala (17) were attributed to SLE.  
Attribution model B (least stringent): NP events which had their onset within 10 years 
of the diagnosis of SLE and were still present within the enrollment window and had no 
“exclusions” and were not one of the NP events identified by Ainiala (17) were attributed 
to SLE. 
By definition, all NP events attributed to SLE using model A were similarly attributed using 
model B. Events which did not fulfill these criteria were classified as non-SLE NP events.  
 
Outcome of Psychosis: For every NP event, a physician generated 7-point Likert scale 
was completed at each follow-up assessment until resolution of the event or patient 
demise (1=patient demise, 2=much worse, 3=worse, 4=no change, 5=improved, 6=much 
improved, 7=resolved) (18). A patient generated SF-36 questionnaire was also completed 
at each assessment and provided subscale, mental (MCS) and physical (PCS) 
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component summary scores (18, 19), that were unavailable to physicians at their 
assessments. 
 
Autoantibodies: Plasma lupus anticoagulant (LAC), serum IgG anti-cardiolipin, anti-β2 
glycoprotein-I, anti-ribosomal P (anti-P) and anti-NR2 glutamate receptor antibodies were 
measured at the Oklahoma Medical Research Foundation, USA as described (20-23).  
 
Statistical analysis: Since there were only 15 patients with psychosis attributed to SLE 
by model A, we used attribution model B and Cox regression to analyze time to first SLE 
psychosis. This included onset of NP events prior to SLE diagnosis in order to capture all 
NP events potentially related to the risk of psychosis. Hazard ratios (HR) and 95% 
confidence intervals (CI) were calculated. Covariates examined included sex, 
race/ethnicity, SLICC sites, post-secondary education, number of ACR criteria at 
enrollment (excluding neurologic disorder), SDI (without NP variables), other concurrent 
NP events and, as continuous variables, age at SLE diagnosis, disease duration (in 
years) and SLEDAI-2K (without NP variables). Binary variables indicating autoantibodies 
present at baseline and follow-up assessments were defined when available. Time-
varying variables, other than those related to autoantibodies, were updated at each 
assessment. When examining the time-varying version of the autoantibody variables, 
autoantibody data in the period before enrolment were imputed by their values at 
enrollment, while autoantibody data at follow-up assessments were imputed by the `last 
observation carried forward’ method.  Kaplan-Meier estimates of the survivor function for 
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the time until resolution of psychosis were calculated.  For analyses of longitudinal SF-36 
subscale and summary scores, linear regression with GEE estimation allowed for 
correlation of observations within patients and adjustment variables include time/visit, 
sex, age at SLE diagnosis, race/ethnicity/location, education, SLEDAI-2K and SDI scores 
(without NP variables), corticosteroids, antimalarials and immunosuppressant use since 
last assessment. 
 
Results 
Patients: 1,826 patients were recruited between October 1999 and December 2011, from 
centers in the United States [n=539 (29.5%)], Europe [n=477 (26.1%)], Canada [n=418 
(22.9%)], Mexico [n=223 (12.2%)] and Asia [n=169 (9.3%)] (Table 1). The number of 
patient assessments varied from 1 to 19 with a mean follow-up of 7.4±4.5 years and final 
assessment follow-up was in March 2017. 
 
Neuropsychiatric (NP) manifestations: NP events (≥1) occurred in 951/1,826 (52.1%) 
patients and 488/1826 (26.7%) had ≥ 2 events over the study period. There were 1902 
unique NP events, encompassing all 19 NP syndromes in the ACR case definitions (14). 
The proportion of NP events attributed to SLE varied from 17.8% (attribution model A) to 
31.1% (attribution model B) and occurred in 13.3% (model A) to 21.1% (model B) of 
patients. Of the 1902 unique NP events, 1742 (91.6%) involved the central nervous 
system and 160 (8.4%) the peripheral nervous system (14). The classification of events 
into diffuse and focal was 1471 (77.3%) and 431 (22.7%) respectively (16). 
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Psychosis: Among 28/1,826 (1.53%) patients with psychosis, 26/28 (93%) had a single 
psychotic event, while one patient each had 2 and 3 discrete events. The majority of 
patients had psychosis attributed to SLE [15/28 (54%) using attribution model A and 25/28 
(89%) using model B]. Patients with lupus psychosis (model B) were located in centers 
from Europe (9 patients), Canada (6 patients), USA (5 patients), Mexico (4 patients) and 
Asia (1 patient). There was no significant association between location and risk of SLE 
psychosis (p=0.53 in Cox regression) taking the number of patients and the duration of 
follow-up at each site into account. The majority of patients with lupus psychosis [20/25 
(80%)] had their first episode either in the year prior to or within 3 years following the 
diagnosis of SLE (Figure 1). There were 31 psychotic events of which 16/31 (52%) and 
28/31 (90%) were attributed to SLE using attribution model A and B respectively. The 
earliest psychotic episode occurred 2 months prior to the diagnosis of SLE. 
 
Clinical and laboratory associations with lupus psychosis: Using Cox regression we 
looked for associations with the risk of the first episode of psychosis attributed to SLE 
using attribution model B. Univariate analysis revealed a positive association [HR 
(95%CI)] between male sex [2.58 (1.04,6.41)], younger age at diagnosis (per 10 years, 
1.36, (1.0,1.88)], African ancestry [4.80 (1.86,12.40)], in particular for patients outside the 
United States [5.53 (1.86,16.42)], concurrent other central [3.86 (1.27,11.70)] or diffuse 
[6.36 (2.12,19.12)] NP events (mood disorder, acute confusional state) attributed to SLE, 
and presence of anti-ribosomal P antibodies at the enrollment visit into the cohort [3.31 
(1.19,9.21)] and over time [3.13 (1.15,8.56)].  
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Important variables identified in univariate analyses were included in multivariate 
analyses, excluding antibody variables due to reduced sample size consequent to 
missing data (Table 2). The significant positive associations [HR (95%CI)] with lupus 
psychosis were similar, namely prior SLE NP events [3.59, (1.16,11.14), male sex [3.0, 
(1.20,7.50)], younger age at SLE diagnosis [per 10 years, 1.45, (1.01,2.07)] and African 
ancestry [4.59 (1.79,11.76)]. Further, after adjusting for the demographic predictors in 
Table 2 (sex, age at SLE diagnosis and race/ethnicity), anti-ribosomal P antibodies at 
enrolment [2.29 (0.81,6.46), p=0.11] and over time [2.17 (0.79,5.97), p=0.13] were no 
longer significantly associated with the risk of lupus psychosis  
 
Treatment of SLE psychosis: The treatment of individual patients was at the discretion 
of their attending rheumatologist and was predicated on the overall needs of the patient 
and not only the psychotic event. The following therapies were used during the time of 
the first psychotic events: corticosteroids 23/28 (82.1%) with a mean (SD) dose of 
prednisone of 21.9 (14.9) mg/day, immunosuppressants (cyclophosphamide, 
azathioprine, methotrexate, mycophenolate mofetil) 17/28 (60.7%), biologics 1/28 (3.6%), 
antipsychotic drugs 19/28 (67.9%), antidepressants 11/28 (39.3%), either/both 
antipsychotic drugs and antidepressants 22/28 (78.6%). In 13/28 (46.4%) events 
corticosteroids had been started prior to the onset of psychosis with a mean (SD) dose of 
20.3 (13.6). 
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Clinical outcome and health related quality of life (HRQoL) in patients with lupus 
psychosis: A summary of physician assessments of outcome of lupus psychosis is 
illustrated in Figure 2. Over 80% of the psychotic events had resolved by the second 
annual assessment following onset of the event (Figure 2a). Likewise, the maximum and 
minimum Likert scores over the duration of follow-up illustrates that the majority of 
psychotic events either improved or resolved over the period of observation (Figure 2b). 
 
The mean (SD) SF-36 PCS and MCS scores are shown in Figure 3a for the following four 
patient groups. Group 1 (n=29): visits in patients with onset of lupus psychosis since last 
assessment or with an ongoing psychotic event; Group 2 (n=3379): visits in patients with 
onset of other NP events since last assessment or ongoing other NP event(s), including 
non-SLE psychosis; Group 3 (n=2180): visits in patients with no NP events since last 
assessment and no ongoing NP event(s) but with a history of previous NP event(s); Group 
4 (n=5893): visits in patients who never had NP event(s). The lowest summary scores 
were in groups 1 and 2 (global p < 0.001 in the multivariate analyses) and the negative 
impact on HRQoL affected all 8 subscales of the SF-36 as show in the accompanying 
spidergram (Figure 3b). 
 
To determine if there was a persistent change in HRQoL following physician determined 
resolution of lupus psychosis, patient generated SF-36 scores were compared in the 
following two groups. Psychosis group (n=29): visits in patients with onset of lupus 
psychosis since last assessment up to its resolution. Resolved group (n=112): visits in 
patients with resolution of lupus psychosis up to their last follow-up or recurrence of 
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psychosis. If the psychotic event had both onset and resolution in the same interval prior 
to assessment, SF-36 scores at that assessment were included only in the psychosis 
group. As illustrated in Figure 4a, there was substantial improvement in both MCS scores 
(mean difference: 7.01) and PCS scores (mean difference: 4.34) and in all subscales of 
the SF-36 (Figure 4b) concurrent with resolution of lupus psychosis 
 
Discussion 
In a large, international, inception cohort study of SLE patients we have prospectively 
documented the frequency, associations and outcomes of psychotic events over a mean 
follow-up of 7.4 years. Our findings confirm and expand upon the results of previous 
cross-sectional and historical studies of psychosis in SLE (6-8, 24, 25). The majority of 
psychotic events were directly attributed to SLE, had a predilection to occur early in the 
course of the disease and were more frequent in male patients. Psychosis was also more 
frequent in those patients of African ancestry as is also the case for non-SLE patients with 
the same race/ethnicity (26). The outcome of lupus psychosis, as determined by both 
physicians and patients, was positive and emphasizes the importance of diagnosing and 
treating this rare manifestation of NPSLE. 
 
Studies of NPSLE conducted prior to the introduction in 1999 of the ACR case definitions 
for NPSLE did not have a uniform definition for psychosis. Using the ACR case definition, 
the frequency of psychosis has been reported to vary between 0% and 17.1% (6, 17, 27-
30) and in our study it was 1.53% (28/1826). Using a well-defined process for determining 
attribution, we confirmed that the majority of psychotic events were due to SLE. In keeping 
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with other NPSLE events and with other severe SLE manifestations such as nephritis 
(31), there was a predilection for psychosis to occur early in the disease course, usually 
within the first 3 years following the diagnosis of SLE. Univariate analysis identified 
significant associations between lupus psychosis and anti-ribosomal P antibodies, 
although following adjustment for demographic variables, the 95% CIs around HRs were 
wide and included the null value, precluding a definitive conclusion regarding association 
of this autoantibody with psychosis. This is consistent with an earlier report on NP events 
in the SLICC inception cohort (32). 
 
The potential role of corticosteroids must also be considered. In the current study, 
exposure to corticosteroids prior to lupus psychosis occurred in less than half of the initial 
events. As per the ACR case definition for psychosis (14), the concurrent use of 
corticosteroids at the onset of psychosis was identified as an “association” rather than a 
firm “exclusion”, indicating uncertainty about the role of corticosteroids in individual cases 
and to allow flexibility for determining attribution. Although NP symptoms have been 
reported with all types and doses of corticosteroids (33), including psychosis following 
intra-articular steroid injections (34, 35), in general the dose of corticosteroids is the most 
important risk factor. In the Boston Collaborative Drug Surveillance Program, the 
frequency of psychiatric symptoms of any type was 18.6% in patients receiving >80 
mg/day of prednisone, 4.6% in patients receiving 41-80 mg/day and 1.3% in those 
receiving <40 mg/day. In the current study, exposure to corticosteroids prior to lupus 
psychosis was in the lowest of these dose ranges. 
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Although the somatic toxicities of corticosteroids are well described, the literature on NP 
effects is considerably less. Their reported frequency varies widely from 2% to 60% (36-
38) and symptoms include affective, behavioural and cognitive manifestations (33). 
Moreover, the term “steroid psychosis” has been used to capture a heterogeneous group 
of NP effects, is not supported by validated diagnostic criteria and previous reports have 
included many patients who were not psychotic. The ACR case definition for psychosis 
(14), used in the current study, is based upon the Diagnostic and Statistical Manual of 
Mental Disorders, Fourth Edition (DSM-IV) (39). In a previous study of 2,069 patients who 
received corticosteroids only 3 (0.14%) developed psychosis using DSM-IV criteria (40).  
 
One of the major advantages of our prospective study was the ability to document the 
short-term impact and long-term outcome of lupus psychosis from the perspective of both 
the physician and patient. In keeping with previous studies (6, 7) the physician 
assessments indicated resolution in the majority of cases with very few recurrences. 
Using a previously validated approach to measure the clinical outcome of NP events in 
SLE (18) we used summary and subscale scores of the SF-36 to assess the patient 
perspective. This is important because physician and patient assessment of outcome for 
other manifestations of SLE (41) and some NP events (42) may be discrepant. Although 
the greatest impact was on MCS scores it was apparent that all subscales of the SF-36 
were negatively impacted in patients with lupus psychosis. However, following treatment 
and in keeping with physician assessment of outcome, the patient generated SF-36 
scores showed a remarkable reversal when averaged over time.  
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There are some limitations to the current study. First, the small number of patients with 
lupus psychosis limited our ability to precisely estimate potential associations with clinical 
or laboratory variables of interest. However, most of the previous studies have had an 
even smaller sample size and the SLICC cohort is the largest inception cohort of SLE 
patients. Second, specialized investigations such as advanced neuroimaging or cytokine 
profiling of CSF were not routinely performed but left to the discretion of individual 
investigators which reflects what is done in clinical practice, a key component of our 
overall SLICC protocol. Third, the observational cohort study design precludes 
determination of optimal therapeutic regimes for lupus psychosis but rather reflects 
current standard of care.  Despite these limitations, the study provides encouraging data 
on the outcome of this rare but potentially devastating manifestation of NPSLE.  
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Legends for Figures 
Figure 1: The relationship between the time of onset of lupus psychosis and diagnosis 
of SLE. 
 
Figure 2: Physician determined outcome of lupus psychosis.  A: Survival curves for 
resolution. B: The highest and lowest Likert scale scores over the duration of follow-up 
are shifted to the right indicating improvement. 
 
Figure 3: Association of SF-36 summary and subscale scores with lupus psychosis. 
A: mean (SD) physical component summary (PCS) and mental component summary 
(MCS) scores in 4 patient groups. Group 1 (n=29): visits in patients with onset of lupus 
psychosis since last assessment or with an ongoing psychotic event; Group 2 (n=3379): 
visits in patients with onset of other NP events since last assessment or ongoing other 
NP event(s), including non-SLE psychosis; Group 3 (n=2180): visits in patients with no 
NP events since last assessment and no ongoing NP event(s) but with a history of 
previous NP event(s); Group 4 (n=5893): visits in patients who never had NP event(s). 
The number of assessments contributing to each bar are aggregated for patients over 
time. 
B: comparison of individual subscale scores in the same 4 patient groups. The SF-36 
subscales are VT = Vitality, SF = Social function, RE = Role emotion, MH = Mental 
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health, PF = Physical function, RP = Role physical, BP = Bodily pain, GH= General 
health. 
 
Figure 4: The long term change in SF-36 summary and subscale scores following 
resolution of lupus psychosis. 
A: mean (SD) physical component summary (PCS) and mental component summary 
(MCS) scores in 2 patient groups.  Psychosis group (n=29): visits in patients with onset 
of lupus psychosis since last assessment up to its resolution. Resolved group (n=112): 
visits in patients with resolution of lupus psychosis up to their last follow-up or 
recurrence of psychosis. If the psychotic event had both onset and resolution in the 
same interval prior to assessment, SF-36 scores at that assessment were included only 
in the psychosis group .The number of assessments contributing to each bar are 
aggregated for patients over time. 
B: comparison of individual subscale scores in the same 2 patient groups. The SF-36 
subscales are VT = Vitality, SF = Social function, RE = Role emotion, MH = Mental 
health, PF = Physical function, RP = Role physical, BP = Bodily pain, GH= General 
health. 
 
 
 
 
